MM-398 + Cyclophosphamide for Solid Tumors

"This medical trial is enrolling 30 minors aged between 12 months and 20 who have been diagnosed with osteosarcoma. In addition, they must meet the following requirements: histological/cytological confirmation of Ewing sarcoma, rhabdomyosarcoma, neuroblastoma or osteosarcoma; evidence of progression after prior therapy in advanced or metastatic setting; measurable/evaluable disease based on RECIST v1.1 criteria; adequate bone marrow reserves, liver function and renal function; full recovery from any prior surgery or cancer treatment regimens. Patients over 18 years will provide written consent while"

"Small cell lung cancer is frequently remedied through MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide. Additionally, this combination has been demonstrated to aid in the treatment of various afflictions such as multiple sclerosis, acute myelocytic leukemia, and colorectal carcinoma."

"Affirmative. The clinical trial's entry on clinicaltrials.gov states that they are currently searching for participants, which was posted in December 2013 and last updated in March 2022. A total of 30 individuals need to be recruited from 7 separate sites."

"Participating patients can now enroll at 7 different clinical sites, with 3 of them located in Dallas, Oklahoma City and Cincinnati respectively. To reduce travel burden on those involved, it is advised that they choose the nearest site possible."

"MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide was first trialed in 1997 at City of Hope Comprehensive Cancer Center. Subsequently, 1593 trials have been completed and 1065 are still active, the majority taking place out of Dallas, Oklahoma."

"To date, this clinical trial is seeking participants. It was first advertised on December 1st 2013 and the most recent update to its information occurred on March 17th 2022 according to data available through clinicaltrials.gov."

"The prerequisites for participating in this research are that patients must be between 12 months old and 20 years old. On the other hand, there exist 705 trials involving minors and 1857 studies concerning individuals above 65."

"Our analytics at Power assigned a score of 1 to the combination therapy MM-398 (Irinotecan Sucrosofate Liposome Injection) and cyclophosphamide due its Phase 1 status, which indicates that there is only limited data available on safety and effectiveness."